Pharmaleaders to Host “Incredible Pharmaleaders 2013, Billion Dreams, Pushing India’s Growth Agenda

Pharmaleaders to Host “Incredible Pharmaleaders 2013, Billion Dreams, Pushing India’s Growth Agenda

6^th Annual Pharmaceutical Leadership Summit & Pharmaleaders Business Leadership Awards 2013 to focus on Indian Healthcare Sector’s Growth Agenda & Policy Reforms

Wednesday,30^th December 2013, Mumbai, Maharashtra, India

: Indian Healthcare & Pharmaceutical Industry’s most awaited & eagerly awaited annual pharma leadership event, the sixth annual Pharmaceutical Leadership Summit & Pharmaleaders’Business Leadership Awards 2013 ( www.pharmaleaders2013.com )  is set to be host in Mumbai, India, at Hotel Hilton Mumbai International Airport on 27^th December 2013 under the theme Incredible Pharmaleaders, Billion Dreams – Pushing India’s Growth Agenda by Asia;s biggest & most analytical news media Pharmaleadrs ( www.pharmaleaders.tv ). Widely perceived by the industry’s experts, the historic sixth edition of the summit will address & deliberate on the most compelling issues the industry is confronting over the last one year by the Industry veterans, Policy Makers, Pharma Academia, Politicians & leading medical experts.

The platform is expected to raise the key questions rather the issues that will grapple the Indian pharma companies as to what are the drivers of the Indian pharmaceutical industry in an era  where Healthcare in india is most neglected as the study reveals 28 percent of the country's population accounts for 31% of all doctors in the country with Delhi leading  the chart with 40,500 doctors alone for a population of 1.6 crore and Haryana has the highest density of 2.3 doctors per 1,000 population.But this does not mean that residents from these states are healthier, that distinction goes to Kerala, which ironically has the lowest doctor density of 1 per thousand amongst the 120 cities. It is equally important that as the industry shrinks to fit a more challenging competitive set, hence the industry  must steer their own way through an obstacle course of opposites that we characterize as "growing to be small." Today, it's all about expanding the business while avoiding bloat, the traditional by-product of success: staying externally focused; eliminating internal barriers to faster decision-making; collaborating with others to defray risks; getting close to the customer, who often wears many hats; and creating dominant therapy positions in multiple niche markets that, when combined, produce equivalent blockbuster results, at lower fixed costs and less hassle.

Announcing the date & theme of the Pharmaleaders’s 6^th Annual Pharmaceutical Leadership Summit & Business Leadership Awards 2013, Satya Brahma, Chairman & Editor-In-Chief of Pharmaleaders said “ While the industry today is at the loggerheads with the Government & various statutory authorities including the regulators such as Drug Administration, market watchdog SEBI & host of other organizations, there is a lack of meaningful dialogue & interaction between the Industry & the Government leading to the bigger uncertainty of the overseas players coming to India with the basket of products & investments due to a weak law & virtual policy paralysis. The issue of Pricing is the biggest factor leading to the discontentment of te Pharma Companies. The unavailability of medicines seen across the country is the major challenge as well.The declining research & drug discovery, Clinical trials are seen as major deterrents”. The Pharmaleaders platform therefore attempts to build the gap of trust deficit & infuse the sense of confidence of the country’s drug makers.

The 6^th Annual Pharmaceutical Leadership Summit & Pharmaleaders Business Leadership Awards will also confer the prestigious annual awards to the rising healthcare leaders & top performing companies.  

Corruption is the biggest Challenge to India’s Growth Story - His Holiness Sri Sri Ravi Shankar

Corruption is the biggest Challenge to India’s Growth Story - His Holiness Sri Sri Ravi Shankar

Friday,23^rd August 2013 : In what could be termed as the biggest message to the business community of 250 odd business tycoons from india & middle east who had gathered at Indo-Arab Chamber of Commerce (IACC)’s Connecting SME’S to the Middle East mainly Investors and entrepreneurs from 23 Arab states planning to build an exclusive investment region near Bangalore with world class facilities for micro, small and medium enterprises (MSME) in diverse sectors of the economy, His Holiness Sri Sri Ravi Shankar said “ What the Nation needs at this point is the elimination of corruption from the top to button which has spread as a disease to the country & the solution lies in cleansing the system with good governance & able administrators” in an exclusive interview to the editorial Chairman Satya Brahma of Network 7 Media Group which runs Asia’s biggest Media Property like Indian Affairs, Breakfastnews, Pharmaleaders, Odisha Affairs & a host of other trade & digital media properties.

Sri Sri Ravi Shankar is known as a great humanitarian leader, spiritual teacher and ambassador of peace. His vision of a stress-free, violence-free society has united millions of people the world over through service projects and the courses of The Art of Living. The message of Sri Sri Ravi Shankar in the sideline of the meet assumes greater significance in view of the current scams the country is grappling leading to policy paralysis.

Investors and entrepreneurs from 23 Arab states plan to build an exclusive investment region near Bangalore with world class facilities for micro, small and medium enterprises (MSME) in diverse sectors of the economy."We plan to build an Arab Investment Region (AIR) in about 400 acres of land near National Highway seven (NH7) and closer to the Bangalore international airport at Devanahalli as investors and entrepreneurs from Arab states are keen to set up MSMEs for exports," Indo-Arab Chamber of Commerce (IACC) chairman S. Krishna Kumar said Friday on the margins of a trade meet here.

The IACC will soon approach the Karnataka government for regulatory approvals to build the region with an integrated township and an ecosystem that will also facilitate local investors to set up MSMEs that will export primarily to Arab states."If the state government is unable to provide land for the region, we will purchase it (land) from private parties at market rate and request the government to provide connectivity, power, water and other facilities to ensure faster turnaround of products for exports," Kumar, who was a former central minister, said.

Earlier, about 40 delegates from the Arab states, participating in the day-long conference on 'Transcending Arabian Borders' (TAB 2013), organised by the IACC, expressed willingness to invest in the region."The Arab investors and entrepreneurs are interested in setting up MSMEs, which ill cater to their respective states in diverse sectors spanning information and communication technology (ICT), biotechnology, agriculture, civil engineering, pharma, power, manufacturing and food-processing," Kumar asserted.Though there is no dearth of funds in the petro-rich Arab states, absence of agro-climatic conditions, lack of natural resources, shortage of skilled manpower and want of domain expertise in the new sectors of the economy have put paid to their efforts to become self-sufficient in foodgrains production, manufacturing and services."Over the years, India has been participating in the economic development of the Arab world by supplying manpower, increasing trade and making a breakthrough in construction and project exports," IACC executive director Asif Iqbal said.

MENA (Middle East and North Africa) region director general Shahran Bin Ahmed said Al Bariz Trading firm from Abu Dhabi would set up a joint venture with the Imen Agro Production Agency to grow food crops in India for consumption in the Arab world."As we do not have agriculture production on the scale it is here (India), we are entering into a tie-up with Imen Agro to cultivate food products under captive farming and develop nurseries that can be replanted in our country to grow similar crops in controlled weather conditions," Ahmed told IANS at the conference.With offices in Dubai and Muscat in Oman, the IACC has about 330 members, including 130 from Arab states, who jointly generate about Rs.100 crore trade comprising merchandise, engineering goods and services.The participating Arab and African states include Bahrain, Brunei, Egypt, Iran, Iraq, Jordan, Kuwait, Lebanon, Libya, Morocco, Oman, Palestine, Qatar, Saudi Arabia, Somalia, Sudan, Syria, Tunisia and UAE."Our Indian members and entrepreneurs, especially in the MSME sector can also explore investing in the Arab world through the GCC (Gulf Cooperation Council), as the sector plays a vital role in improving the quality of life in both societies," Iqbal observed.Union Minister of State for SMEs K.H. Muniyappa inaugurated the conference.

Sudar Industries Wins ILC Power Brand 2013 as Emerging Company of the Year in Textiles

Sudar Industries Wins ILC Power Brand 2013 as Emerging Company of the Year in Textiles

Murugan Muthiah Thevar Led Sudar Industries Wins the coveted Emerging Company of the Year in Textiles  at 4th Annual India Leadership Conclave & Indian Affairs Business Leadership Awards 2013

Mumbai, Maharashtra,Tuesday,9th July 2013 : Sudar Industries Limited BSE Code 533332, NSE Symbol,SUDAR, ISIN: INE384L01017, one of the most promising company in the textiles & Garment sector with a group turnover of more than 150 Crore & making a strong inroads into the domestic & international market has been conferred by the Juries of Indian Affairs (www.indianaffairs.tv  ) as the Emerging Company of the Year in Textiles at the historic 4th edition of India Leadership Conclave & Indian Affairs Business Leadership Awards 2013 ( www.indialeadershipconclave.net/2013  ) held in the commercial capital of Mumbai on Friday 21st June 2013 at Asia’s biggest leadership conclave where more than 300 iconic leaders were present in a day long conclave.

Sudar Industries has reported a standalone sales turnover of Rs 126.45 crore and a net profit of Rs 12.20 crore for the quarter ended Dec '12.Sudar Industries has given 139.38% returns over the last 6 months and 102.20% over the last 12 months. Receiving the prestigious title, Mr. Murugan Muthiah Thevar, founder chairman & MD of Sudar Industries said “ As a emerging company, Sudar has always maintained the quality keeping the latest trends in innovation & using world-class innovation in bringing new products in the market & as Sudar attempts to penetrate the newer market in the international foray, Sudar has set a target to reach 500 Crore by 2014”.

Sudar Industries is as an integrated apparel manufacturer with the established capability to design and manufacture readymade garments across the value chain comprising cutting, body stitching, washing, ironing and finishing.Sudar  reported a 68.67 per cent growth in revenues and 90 per cent growth in profit after tax in 2011-2012 from the garment operations. This validated the trustin the ability to grow  business using stakeholders capital. acquired the Land & Building and Plant & Machineries of Benzo Petro International Ltd., [BPIL] a Company engaged in the manufacture of petrochemical products promoted by technocrat promoters from GAMI FAMILY comprising of Shri D.C. Gami and Shri Ramesh C. Gami through preferential issue to BPIL.The company specialises in the manufacture of shirts, trousers and a range of other apparel for men, women and kids. The company manufactures and markets apparel under its own brand called Glory to Glory. The Company also engages in contract manufacture for domestic brands and merchant exporters.Its Products include Men's and kids wear: Plain shirts, striped shirts, trousers, casual wear, knit wear, patchwork shirts, embroidery shirts, mix and match shirts, denim and cargos Women's wear: Ladies shirts, casual wear, knit wear and tank tops Industry Structure and Developments Global textile industry.The global textile market grew 6.3 per cent in 2011 to USD 630.6 billion. In 2016, the global textile market is expected to reach USD 833.9 billion, an increase of 32.2 per cent over 2011. Fabric accounts for the largest segment of the global textile market, accounting for 82 per cent of the market's total value. Asia-Pacific accounts for 60.7 per cent of the global textile mills market value.Textile production has gradually shifted from developed / western countries to developing asian countries rapidly in the last 10 years

Mr. Murugan Muthiah Thevar is the founder and Promoter of our Company. He has completed his matriculation from Tamil Nadu. He is currently the Chairman and Managing Director of our company. He has been associated with the apparel manufacturing business since 1992. Initially, Mr. Murugan Muthiah Thevar commenced business of manufacturing of readymade garments on job work basis for the exporters through a proprietary concern named 'Sudar Industries'. Over a period of time due to expansion of the customer base, increase in demand for readymade garments, and to gain advantage of having all the outsourced activity under one umbrella, restructuring of the business was carried out. Accordingly, on January 28 2002, Sudar Industries Private Limited was incorporated under the Companies Act, 1956 by him. He is responsible for developing business strategies and instrumental in formulating strategic growth of our company. He is responsible for conceiving new and modern innovations in processing fabrics for use in the manufacture of garments.

Mr Kewal Handa, Former Pfizer Chief, Dr Mukesh Batra, CMD, Dr Batra’s & Mr Satya Brahma, Chairman & Editor-In-Chief of Indian Affairs gave away the coveted honors to Sudar Industries in a glittering award ceremony.

Renowned Cosmetic Dermatologist Dr. Nilayini Crowned Skincare Innovation Award at ILC 2013 Power Brand

Renowned Cosmetic Dermatologist Dr. Nilayini Crowned Skincare Innovation Award at ILC 2013 Power Brand

                                                                                  

Dr. Nilayini of Blu Skin & Cosmetology Felicitated For Her Outstanding Contribution to Skincare Innovation at 4^th Annual India Leadership Conclave & Indian Affairs Business Leadership Awards 2013.

Mumbai, Maharashtra, India, Sunday, 30th^th June 2013: While India has to its credit many top Dermatologists & Cosmetic Surgeons, the talent & innovation of the unrecognized faces often go ignored rather unnoticed due to the presence many page three celebrities, one such name the research team of Indian Affairs ( www.indianaffairs.tv ) spotted in the city of Hyderabad who has made the clinic a place for breakthrough research & innovation in the skincare treatment & relentlessly pursued the passion to excel in treatment process rather than showing off. The Jury members of the Indian Affairs team who after checking the credentials, put forth the name of Dr Nilayini to the five finalists who made it to the top five nominations. In the nomination there were names like Dr Shuba Dharmana, Consultant Dermatologist, Hair Transplant Surgeon, Laser Specialist of Dr.Shuba Skin & Laser Clinic rebranded as LE'JEUNE MEDSPA, & Dr. Rashmi Soni Lohiya, Head and consultant dermatologist, Cosmetologist.CEO, Dermato surgeon, Skinsure Clinic, Dr. Tripti Rathore,Master of Science Dermatology, ,Clinical Director & Lead Dermatologist, Uday Preet Sidhu. Consultant Dermatologist & Cosmetologist in the race for the coveted award. To the surprise to many, Dr Nilayani of Blu Skin trounced all the nominees won the prestigious title with a thumping voting by the public putting the name as No 1 Cosmetic Dermatologist in Hyderabad. The name was declared on the glittering award night on 21^st June 2013 in Mumbai in star-studded power-packed leaders & captains of the mains tram Indian inc.

It is pertinent here to note that since the institutionalization of the Business Leadership Awards in 2010, India Leadership Conclave & Indian Affairs Business Leadership Awards has been India’s most awaited & world’s most respected set of Awards conferred to Companies & Individuals who have made their mark through their remarkable performances despite all odds & have made India Proud!. Since the last three successful years, the platform has recognized, felicitated more than 300 fortune 500 Companies & towering captains & Leaders of the Country. Widely perceived by Asia as a centre point of discussion, India Leadership Conclave platform too has witnessed deliberation by top business tycoons, politicians, Bureaucrats, Social Reformers etc.

Dr Nilayini is the founder,of Blu Skin & is the prestigious member of American Society of Aesthetic and Cosmetic Physicians. Dr. Nilayini has been accredited nationally and internationally in various advanced cosmetic procedures like Fillers and Botox. She started Blu Skin & Cosmetology – the first of its kind, in the high profile area of Hyderabad ie Jubilee Hills, an abode to many niche clients in and around Hyderabad and from other cities & countries. Blu Skin & Cosmetology is the pioneer among the Beauty Medical Spas in Hyderabad, in terms of facilities , infrastructure & services offered. Blu Skin & Cosmetology was inaugurated by the legendary actor Akkineni Nagarjuna. The aesthetic caliber that Dr Nilayini possesses is far beyond questioning , and with the patient success reviews she gets about Blu Skin & Cosmetology, it is beyond doubt that Dr Nilayini is the prime & hard force in the reckoning, especially in the field of aesthetic cosmetology. Blu Skin & Cosmetology Clinic is the first in Hyderabad to receive the certificate of appreciation as a notable name & is accredited with ISO 9001 & 2008.

Receiving the honor from the hands of Satya Brahma, Chairman of Network 7 Media Group & Dr Mukesh Batra, the legendary Global Leader in Homeopathy, Dr Nilayini said “The field of Skincare treatment is often misunderstood as an expensive proposition as many Dermatologists have turned to glamour & term it as a complex art, Blu Skin is one of very few that term that the treatment in skincare process in affordable to the huge rising middle class & Blu Skin has been offering the services to the people who thought that it was beyond their reach after snubbed by many in the profession, Indian Affairs has recognized this small aspect & the journey will continue to the fullest extent & will expand into a pan India network”.

Ranbaxy Receives Rare Distinction at ILC Power Brand 2013

Ranbaxy Receives Rare Distinction at  ILC Power Brand 2013

Ranbaxy CEO Arun Sawhney Is Declared the CEO of the Year, Volini,Revital & Chericof Cough Syrup Voted Power Brands at 4^th Annual India Leadership Conclave & Indian Affairs Business Leadership Awards 2013

Mumbai, Maharashtra, India, Saturday, 29^th June 2013: Indian Pharma Major Ranbaxy, Country’s biggest & largest drug maker Ranbaxy shined at the historic platform of Indian Affairs Business Leadership Awards 2013 as it bagged the coveted CEO of the Year to its dynamic & aggressive CEO & MD, Mr Arun Sawhney under open public voting that ran for 60 days in 17 states & 3 countries by the Indian Affairs Juries, independent experts declared Ranbaxy as Winner at the closing ceremony of the glittering Award Night. Organized by Network 7 Media Group’s Indian Affairs in association with Breakfastnewstv, Pharmaleaders, Ranbaxy Global Consumer Healthcare (RGCH) which has been at the forefront of maintaining leadership position in the OTC market has been voted by the general public in the open nomination category for its successful brands Revital,Volini & Cheridof syrup. Ranbaxy which has been in the news post Daiichi-Sankyo takeover from Singh Brothers has expanded its base under the dynamic leadership of its CEO Arun Sawhney.

Ranbaxy Global Consumer Healthcare (RGCH) received two coveted & prestigious Awards at the power-packed gatherings with Chericof receiving the Emerging Brand of the Year & Volini & Revital as Brands of the Decade. The honor  came after the sixty days of voting by the public conducted by the Research team of Indian Affairs, It may be recalled that Ranbaxy is India’s largest pharmaceutical company and has a product portfolio that covers all major therapy areas, including Anti-infectives, Nutritional, Gastrointestinal, Pain management, Cardiovascular & Diabetes, Dermatology, Urology and Central Nervous System (CNS). Ranbaxy has also have a strong presence in the Novel Drug Delivery System (NDDS) segment. Incorporated in the year 1961 with more than 200 Molecules with some Leading Molecules such as Sporidex (Cephalexin), Cifran (Ciprofloxacin), Mox (Amoxycillin), Zanocin (Ofloxacin), Storvas (Atorvastatin), Oframax (Ceftriaxone), Cepodem (Cefpodoxime), Moxclav (Amoxicillin+Clavulanic Acid), Cilanem (Imipenem+Cilastatin), Volini (Diclofenac combination), Silverex (Silver Sulphadiazine), Cepodem (Cefpodoxime), Volini (Diclofenac), Revital (Nutritional)

Receiving the prestigious honors at the Conclave, Mr. Brijesh Kapil, Vice-President of Ranbaxy Global Consumer Healthcare (RGCH) said “Ranbaxy Global Consumer Healthcare (RGCH) which is a separate business division through which Ranbaxy develop and market Over-the-Counter (OTC) products in more than 20 countries across Asia, Africa, the Middle East and Europe. This division is one of Ranbaxy fastest growing and offers 15 products, including some top-selling brands that have leadership status in their respective segments. Some of Ranbaxy key OTC brands are Revital, Volini, Faringosept, Aspenter and Chericof. RGCH commenced its operations in 2002 with the launch of Pepfiz, Gesdyp and Garlic Pearls in the Indian market. The portfolio was strengthened with the addition of Revital. In 2005, Chericof was added to the offering and, in 2007, Volini, a topical analgesic brand, was introduced. Today, Revital, Ranbaxy flagship brand in the OTC segment, is India’s largest selling Vitamins & Minerals Supplement. It is also among the Top 5 OTC brands of India. Volini is among the fastest growing pain relievers available in India. It is also counted amongst the Top 10 brands in the Indian pharmaceutical market. Some of Ranbaxy other key OTC brands are Revital Woman, Volini Activ and Revitalite. At RGCH, Ranbaxy strive relentlessly to enhance the Ranbaxyll-being of consumers by providing innovative healthcare solutions. Ranbaxy follow the model of staying in constant touch with the market through research and responding to its needs through appropriate products. The division has an aggressive sales and distribution strategy that involves penetrating Class II towns directly and smaller towns through the ‘hub and spoke’ model. Ranbaxy pursue a differentiated sales and distribution strategy of engaging FMCG/OTC distributors for Ranbaxy OTC products. The distribution infrastructure continues to grow, with about 1000+ distributors and sales representatives covering outlets that account for more than 90% of category volumes for all Ranbaxy major OTC brands”.

Addressing the audience which comprised of more than 300 iconic leaders at the India Leadership Conclave platform, after receiving the CEO of The Year Award trophy bestowed to Mr Arun Sawhney, on behalf of its CEO & MD , Mr. Arun Sawhney, Brijesh said “Mr. Sawhney is an industry veteran, with over three decades of international experience in the Chemical and Pharmaceutical arena. He has held senior functional and management positions in global pharmaceutical companies like Max-Gb, Hindustan Ciba-Geigy, Bayer India Limited and Dr. Reddy’s Laboratories Limited & Mr. Sawhney is one of the founder members of the Pharmaceuticals Export Promotion Council of India (Pharmexcil) and is currently a member of the Advisory Board of the United States Pharmacopeia (USP) in India. He is also the Chairman of the Confederation of Indian Industry (CII)’s National Committee on Pharmaceuticals and a Member of the India-Malaysia CEO Forum, the India-South Africa CEO Forum and the India Africa Business Council constituted by the Government of India. Mr. Sawhney has been Chairman of the Pharmaceutical Committee of the Federation of Indian Chambers of Commerce and Industry (FICCI). Mr Sawhney has been instrumental in the success story of Ranbaxy”.

Mr Kewal Handa, Former Pfizer Chief, Dr Mukesh Batra, CMD, Dr Batra’s & Mr Satya Brahma, Chairman & Editor-In-Chief of Indian Affairs Ranbaxyre present to give away the coveted honors to the Ranbaxy.

Upinder Zutshi of Infinite Computers is the CEO of The year at ILC 2013

Upinder Zutshi of Infinite Computers is the CEO of The year at ILC 2013

Infinite Computer Solutions Shines at India Leadership Conclave 2013 as a Top Achiever for its Consistent & Sustainable Leadership Position as a Leading IT Software Solution Provider.

Mumbai, Maharashtra, India, Thursday, 27th June 2013:Managing Director & CEO of Infinite, Mr.UpinderZutshi was adjudged ‘CEO of the Year’ and Infinite was adjudged as India’s ‘Most Respected Company in Corporate Governance and Excellence’ at the4^th Annual India Leadership Conclave & Indian Affairs Business Leadership Awards 2013 (www.indialeadershipconclave.net/2013) organized by Asia’s most analytical news media,Indian Affairs ( www.indianaffairs.tv ) in association with the Ministry of Corporate Affairs, Government of India on Friday,21^st June 2013 at Hotel Leela in Mumbai, India.

Network 7 Media Group which organized its historic 4th Edition of India Leadership Conclave 2013 had leading faces of India addressing the conclave under the theme “New India, Agenda For Change”. More than 300 business tycoons, diplomats, politicians, social reformers & delegates from across the society attended the high profile leadership event that was set to throw new directions to new India. Widely perceived in Asia as central theme of discussion on serious issues, the event also saw the presence of overseas leaders from Europe, Middle East & ASEAN Countries. The award was conferred under open public voting that ran for 60 days in 17 states & 3 countries by the Indian Affairs Journalists & independent experts who declared the winners at the closing ceremony of the glittering Award Night.

Infinite Computer Solutions received two coveted & prestigious awards at the power-packed gathering with its MD &CEO Mr. UpinderZutshi receiving the CEO of the Year Award & Infinite as “India’s Most Respected Company in Corporate Governance & Excellence” by the leading & eminent Jury.

Receiving the prestigious honors at the Conclave, Mr. UpinderZutshi said “We began as a small enterprise at the beginning of the century and have certainly come a long way since. I humbly accept the award on behalf of all those that have been a part of the journey including our Board of Directors, members of our Senior Management and the 5000+ ‘Infinitians’ spread across the globe, who have made this journey successful. As we mark this occasion, there is reason to celebrate and recommit ourselves toward future successes!”

The Conclave also felicitated individuals & companies from different sections of the society such as Agriculture, Automobiles, Auto Components, Aviation, Education and Training, Engineering, Financial Services, Food Industry, Insurance, IT &ITeS, Manufacturing, Media and Entertainment, Retail, Science and Technology, Banking, Biotechnology, Cement, Consumer Markets, Healthcare, Infrastructure, Oil and Gas, Pharmaceuticals, Real Estate & Infrastructure, Steel, Textiles, Telecommunications, Tourism and Hospitality where more than 45 iconic leaders were felicitated. Among notable awardees included veterans like Mr. Ratan Tata, Mr. MukeshAmbani, Actress Priyanka Chopra, Fashion Designer Mr. Manish Malhotra, Dr. MukeshBatra, Dr. MukeshHariawala, Dr. Laud etc.

Mr. KewalHanda, Former Pfizer Chief, Dr. MukeshBatra, CMD, DrBatra’s&Mr. Satya Brahma, Chairman & Editor-In-Chief of Indian Affairs were present to give away the coveted honors to the Awardees.

Zuventus Healthcare, Wanbury, Macleods Pharma In Race For the Emerging Healthcare Company at ILC 2013

Zuventus Healthcare, Wanbury, Macleods Pharma In Race For the Emerging Healthcare Company at ILC 2013

India Leadership Conclave brings tough competition as Indian Pharma Majors Wanbury, Macleods, Bluecross,Wallace & Zuventus Healthcare eye to win the coveted India’s Emerging Healthcare Company of the Year 2013 Title

Mumbai, Maharashtra, India, Friday, 7^th June 2013 : In the run up to the 4^th Annual India Leadership Conclave & Indian Affairs Business Leadership Awards 2013 (www.indialeadershipconclave.net/2013 ) organized by Indian Affairs ( www.indianaffairs.tv ) in association with the Ministry of Corporate Affairs, Government of India & several trade bodies, to be held in Mumbai at Hotel The Leela, Grand Ball Room, on Friday,21^st June 2013 in India, the prestigious nomination for the prestigious “India’s Emerging Healthcare Company of the Year 2013 Award title”has picked up the speed as the Nation votes to select the Winner out od top five finalists screened. The five pharma majors who are in the race are all Mumbai based companies such as Wanbury Ltd,Macleods Pharmaceuticals Limited, Blue Cross Laboratories Ltd,Wallace Pharmaceuticals Ltd,Zuventus Healthcare Ltd.

Given to vote by the Juries to taste the mood of the nation since last 45 days, the much awaited Leadership Conclave titled The New India – Agenda For Change, Indian masses have been voting to chose the Companies & Individuals who has been remarkably successfully in the various categories such as telecommunication,IT,Education &Training, Pharmaceutical, Healthcare, Food & Beverages, Automobile, Power (Incl Renewable),Chemical & Fertilizer,FMCG & Consumer Appliances, Hotel, Hospitality, Travel & Tourism, Financial Sector – Banking/Non Banking finance companies/asset Management companies, BPOs (Business Process Outsourcings) etc. “India’s Emerging Healthcare Company of the Year 2013 Award Nomination is being widely discussed as Indian Healthcare Industry is in news following two major developments first on the Novartis Patent Ruling & Ranbaxy’s alleged violation of safety norms in medicines.

India is now among the top five pharmaceutical emerging markets. The Indian pharma industry has been growing at a compounded annual growth rate (CAGR) of more than 15 per cent over the last five years and has significant growth opportunities. The domestic pharmaceutical market is expected to register a strong double-digit growth of 13-14 per cent in 2013 on back of increasing sales of generic medicines, continued growth in chronic therapies and a greater penetration in rural markets.The cumulative drugs and pharmaceuticals sector has attracted foreign direct investments (FDI) worth US$ 10,308.75 million during April 2000 to February 2013, according to the latest data published by Department of Industrial Policy and Promotion (DIPP). Under these contexts, all five pharmaceutical companies such as Wanbury Ltd,Macleods Pharmaceuticals Limited, Blue Cross Laboratories Ltd,Wallace Pharmaceuticals Ltd,Zuventus Healthcare Ltd. Have peformed well in the market & since the real winner is the one who beats all odds & perform exceptional growth will be crowned the glory said, Award Nomination Committee Chairman Satya Brahma.

Mumbai baseds Drug maker Wanbury, has reported a standalone sales turnover of Rs 105.35 crore and a net loss of Rs 8.20 crore for the quarter ended Dec '12. Other income for the quarter was Rs 0.03 crore.For the quarter ended Dec 2011 the standalone sales turnover was Rs 76.10 crore and net loss was Rs 13.41 crore.. Recently CCI is probing Macleods pharma among five entities for 'engaging in anti-competition practices' in granting stockist licence for medicines in Himachal Pradesh. Macleods has its presence in over 30 countries with more than 300 registrations. The export range of Macleods are manufactured in a unit that has QSM approval from WHO-Geneva, and certifications from various International Regulatory Authorities like - USFDA, MCC, UKMHRA, MOH Belarus, INVIMA Colombia, National Drugs Authority - Uganda, Food and Drugs Board - Ghana, MCAZ Zimbabwe, Pharmacy and Poisons Board Kenya, Pharmacy Board Tanzania etc. Owing to a high degree of technological advancements, Macleods offers quality health care worldwide. It has strong presence in essential therapies like TB, malaria & HIV. Wanbury Ltd is the fastest growing pharma company with a Compounded Annual Growth Rate(CAGR) of 68% over the last 6 years.The company has strong presence in domestic formulations,Active Pharmaceutical Ingredient(API) and Contract Research and manufacturing Services(CRAMS).The company also has its presence in Europe in formulations & the company has opened its office in Zurich,Switzerland for its CRAMS business and incorporated Wanbury Global FZE in Middle East for carrying out its trading activities in the year 2008.   Indchemie health specialities pvt. Ltd has been in the ethical pharma business for more than two decades now, with leadership in few of the segments. It has a strong back up of in-house manufacturing facility & has four pharmaceuticals manufacturing units & the beta-lactam unit is having several commendable approvals from african regulatory agencies like ethiopia, kenya and Malawi. Its business focus is backed with the building up of captive manufacturing operations and of complying with the regulatory standards of the advanced markets.

Blue Cross Laboratories Ltd is a leading Indian pharmaceutical company. This research based organization boasts of more than two decades of sterling performance in the arena of healthcare products. The company serves a global client base. The company operations run on SAP. The Corporate office is connected with the production factories through RF MPLS. The company has an annual sales turnover of around Rs.250 Crore. The company employee base comprises over 1000 people. The Wallace Group is a privately owned Pharmaceutical & Biotechnology Group headquartered in Goa, India. Incorporated in the late 1960s as a joint venture with Carter Wallace Inc. and Menezes family, the Wallace Group is primarily engaged in the manufacture and marketing of formulation products in India as well as abroad. The Group comprises Wallace Pharmaceuticals, Indipharma and Goodwin Biotechnology Inc. The Wallace Group employs over 2300 personnel with offices and facilities in several key locations in India and around the world. The Wallace Group comprises of Wallace Pharmaceuticals , Wallace Laboratories, Indi Pharma, GoodWinBio Tech & Trusts. Prakash Guha led Zuventus Healthcare Limited is one of the fasdtest growing pharmaceutical company with an enviable position in the Indian Healthcare Space with the turnover of more than 650 Crore. Zuventus Healthcare is a Joint Venture Company with Emcure, a leading pharma giant & employs more than 2500 people & has a huge presence of its products in pan India network.

The Grand Final of the Winner for the the Emerging Healthcare Company of the year Award will be announced on Friday,21^st June 2013 at the Grand Ball Room of the Hotel Leela in Mumbai, India